Gastric Ulcers - Pipeline Review, H2 2016

Publisher Name :
Date: 14-Sep-2016
No. of pages: 43
Inquire Before Buying

Global Markets Direct's, ‘Gastric Ulcers - Pipeline Review, H2 2016', provides an overview of the Gastric Ulcers pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Gastric Ulcers, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Gastric Ulcers and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Gastric Ulcers

  • The report reviews pipeline therapeutics for Gastric Ulcers by companies and universities/research institutes based on information derived from company and industry-specific sources

  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

  • The report reviews key players involved Gastric Ulcers therapeutics and enlists all their major and minor projects

  • The report assesses Gastric Ulcers therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

  • The report summarizes all the dormant and discontinued pipeline projects

  • The report reviews latest news related to pipeline therapeutics for Gastric Ulcers

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Identify and understand important and diverse types of therapeutics under development for Gastric Ulcers

  • Identify potential new clients or partners in the target demographic

  • Develop strategic initiatives by understanding the focus areas of leading companies

  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

  • Devise corrective measures for pipeline projects by understanding Gastric Ulcers pipeline depth and focus of Indication therapeutics

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Gastric Ulcers - Pipeline Review, H2 2016

Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Gastric Ulcers Overview 6
Therapeutics Development 7
Pipeline Products for Gastric Ulcers - Overview 7
Gastric Ulcers - Therapeutics under Development by Companies 8
Gastric Ulcers - Pipeline Products Glance 9
Clinical Stage Products 9
Early Stage Products 10
Gastric Ulcers - Products under Development by Companies 11
Gastric Ulcers - Companies Involved in Therapeutics Development 12
Ache Laboratorios Farmaceuticos S/A 12
Astellas Pharma Inc. 13
ChoDang Pharm Co., Ltd. 14
Kukje Pharmaceutical Industry Co., Ltd. 15
XuanZhu Pharma Co., Ltd. 16
Gastric Ulcers - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Combination Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 24
Drug Profiles 25
(ecabet + ranitidine) - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
anaprazole sodium - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
ASP-6537 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
KJ-14001 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
PDI-39 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
PMKS-005 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
Small Molecules for Gastric Ulcers - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
Gastric Ulcers - Dormant Projects 32
Gastric Ulcers - Discontinued Products 33
Gastric Ulcers - Product Development Milestones 34
Featured News & Press Releases 34
Jul 17, 2013: Sihuan Pharmaceutical Secures SFDA Approval for Anaprazole Sodium Category 1.1 New Drug Clinical Studies 34
Mar 01, 2010: AstraZeneca Provides An Update On The Status Of Its Arrangements With Merck 35
Jan 07, 2010: AstraZeneca Reaches Agreements with Teva Pharmaceuticals Regarding Nexium And Prilosec US Patent Litigations 35
Apr 15, 2008: AstraZeneca Settles US Nexium Patent Litigation with Ranbaxy 35
Feb 28, 2008: AstraZeneca Provides An Update on the Status of its Arrangements With Merck & Co., Inc. 36
Dec 10, 2007: FDA Concludes There Is No Increased Risk Of Cardiac Events For Patients Treated With Omeprazole And NEXIUM (Esomeprazole Magnesium) 37
Jun 01, 2007: AstraZeneca's Prilosec Patents Upheld By Court 37
Dec 12, 2003: Astrazeneca Prilosec Patents Upheld by Federal Appeals Court 38
Aug 08, 2003: Astrazeneca to Seek Triple Damages in Patent Infringement Lawsuit Against Mylan Pharmaceuticals 38
Oct 23, 2001: Prilosec US litigation 39
May 02, 2001: Astrazeneca Receives Six Months' Market Exclusivity for Prilosec 39
May 02, 2001: Court Denies Generic's Application for Summary Judgement on Prilosec Patent 39
Apr 23, 2001: Astrazeneca Files Lawsuit Against Apotex Corporation and Torpharm for Patent Infringement 39
Dec 19, 2000: Astrazeneca Wins Losec Patent Litigation in Canada 40
Oct 20, 2000: Joint FDA Advisory Committee Confirms OTC Prilosec (Omeprazole) Safety and Efficacy 40
Appendix 42
Methodology 42
Coverage 42
Secondary Research 42
Primary Research 42
Expert Panel Validation 42
Contact Us 42
Disclaimer 43

List of Tables

Number of Products under Development for Gastric Ulcers, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Clinical Stage Development, H2 2016 9
Comparative Analysis by Early Stage Development, H2 2016 10
Products under Development by Companies, H2 2016 11
Gastric Ulcers - Pipeline by Ache Laboratorios Farmaceuticos S/A, H2 2016 12
Gastric Ulcers - Pipeline by Astellas Pharma Inc., H2 2016 13
Gastric Ulcers - Pipeline by ChoDang Pharm Co., Ltd., H2 2016 14
Gastric Ulcers - Pipeline by Kukje Pharmaceutical Industry Co., Ltd., H2 2016 15
Gastric Ulcers - Pipeline by XuanZhu Pharma Co., Ltd., H2 2016 16
Assessment by Monotherapy Products, H2 2016 17
Assessment by Combination Products, H2 2016 18
Number of Products by Stage and Target, H2 2016 20
Number of Products by Stage and Mechanism of Action, H2 2016 22
Number of Products by Stage and Route of Administration, H2 2016 23
Number of Products by Stage and Molecule Type, H2 2016 24
Gastric Ulcers - Dormant Projects, H2 2016 32
Gastric Ulcers - Discontinued Products, H2 2016 33

List of Figures

Number of Products under Development for Gastric Ulcers, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Clinical Stage Development, H2 2016 9
Comparative Analysis by Early Stage Products, H2 2016 10
Assessment by Monotherapy Products, H2 2016 17
Number of Products by Targets, H2 2016 19
Number of Products by Stage and Targets, H2 2016 19
Number of Products by Mechanism of Actions, H2 2016 21
Number of Products by Stage and Mechanism of Actions, H2 2016 21
Number of Products by Stage and Molecule Types, H2 2016 24
  • Global Gastroparesis Drugs Market Size, Status and Forecast 2022
    Published: 06-Oct-2017        Price: US 3300 Onwards        Pages: 99
    This report studies the global Gastroparesis Drugs market, analyzes and researches the Gastroparesis Drugs development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like - GlaxoSmithKline - Johnson & Johnson - Cadila Pharmaceuticals - Valeant - Evoke Pharma - Teva Pharmaceutical Industries - Theravance Biopharma Market segment by Regions/Cou......
  • Global Chronic Idiopathic Constipation Drug Market Forecast 2017-2025
    Published: 24-Sep-2017        Price: US 2500 Onwards        Pages: 122
    Key Findings Global Chronic Idiopathic Constipation drug market is estimated to grow at a CAGR of 8.37% during the forecast period of 2017-2025. The important drivers propelling the market growth are the modern dietary habits, rising elderly population and the improved and efficient drugs in the pipeline. Linaclotide is the major type of drug popular in this market. Market Insight The CIC drug market is segmented based on drug types and also on the basis of prescript......
  • Global Opioid Induced Constipation Drug Market Forecast 2017-2025
    Published: 24-Sep-2017        Price: US 2500 Onwards        Pages: 125
    Key Findings Global Opioid-Induced Constipation (OIC) drug market is estimated to grow at a CAGR of 7.08% during the forecast period of 2017 - 2025. The major drivers responsible for the market growth include the growing use of opioid, rising geriatric population, growing opioid prescription in North America and Europe, detection of safety threats and the easy availability of improved and effective OIC drugs. Some of the commonly prescribed opioids are Percocet, Vicodin, and codeine.......
  • Asia-Pacific Chronic Idiopathic Constipation Drug Market Forecast 2017-2025
    Published: 24-Sep-2017        Price: US 1250 Onwards        Pages: 67
    Key Findings The Asia-Pacific chronic idiopathic constipation drug market is predicted to expand at a CAGR of 10.30% over the forecast period of 2017-2025. The revenue generated by the market is expected to rise from $683 million in 2016 and reach $1615 million by 2025. MARKET INSIGHTS The Asian CIC drug market can be segmented by the type of drug and by the type of prescription. The drug lubiprostone is dominating the drug segment closely followed by the drug linaclotide. B......
  • Europe Chronic Idiopathic Constipation Drug Market Forecast 2017-2025
    Published: 24-Sep-2017        Price: US 1250 Onwards        Pages: 65
    Key Findings The Europe chronic idiopathic constipation drug market is estimated to grow at a CAGR of 8.80% during the forecast years of 2017-2025.The market value is estimated to increase from $1283 million in 2016 and reach $2721 million by 2025. Market Insights The market has plenty of growth opportunities owing to the unmet needs of CIC drugs in certain countries. The market can be segmented into two types on the basis of the type of prescriptions and the type of drugs. ......
  • North America Chronic Idiopathic Constipation Drug Market Forecast 2017-2025
    Published: 24-Sep-2017        Price: US 1250 Onwards        Pages: 68
    Key Findings The North America Chronic Idiopathic Constipation Drug Market is expected to grow at a CAGR of 6.92%. The market value is expected to rise from $1822 million in 2016 to $3358 million by 2025. The changing modern dietary habits, chances of cancer or other systematic disease leading to CIC and the growing increasing elderly population are some of the factors driving the market. Market Insights The North America chronic idiopathic constipation drug market i......
  • Asia Pacific Opioid Induced Constipation (OIC) Drug Market Forecast 2017-2025
    Published: 24-Sep-2017        Price: US 1250 Onwards        Pages: 65
    Key Findings The Asia-Pacific Opioid Constipation Drug market is estimated to grow at a CAGR of 8.99% during the forecast period of 2017-2025. The market worth is expected to increase from $797 million in 2016 and reach $1708 million by 2025. The ease of the availability of new and improved drugs and the growing geriatric population are currently driving the Asian Market. Market Insights The Asian market can be classified on the basis of drug type and prescription type. The ......
  • Europe Opioid Induced Constipation (OIC) Drug Market Forecast 2017-2025
    Published: 24-Sep-2017        Price: US 1250 Onwards        Pages: 62
    Key Findings The Europe opioid-induced constipation drug market is expected to grow at a CAGR of 7.51% during the forecast period of 2017-2025. The market value is predicted to increase from $1497million in 2016 and reach up to $2877 million by the end of 2025. Market Insights The Europe opioid constipation drug market is mainly driven by the increasing opioids prescription in the region. The market can be segmented into two criteria. First is the market by drug type that in......
  • North America Opioid Induced Constipation (OIC) Drug Market Forecast 2017-2025
    Published: 24-Sep-2017        Price: US 1250 Onwards        Pages: 65
    Key Findings The North America opioid-induced constipation drug market is expected to command the global OIC drug market during the forecast period of 2017-2025 with an expected CAGR growth of 5.65%. The revenue generated by the market is expected to increase from $2125 million in 2016 and reach $3551 million by 2025. Market Insights The North American OIC drug market is segmented on the basis of the type of prescription and the type of drug. The prescription type market is ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs